|
|
QLT Inc. - Company Profile Snapshot
| Company Profile: |
QLT Inc. |
| Ticker: |
QLT |
| Exchanges: |
NAS MON TOR |
| 2007 Sales: |
135,830,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
CANADA |
| Employees: |
199 |
Business Description
QLT Inc.. The Group's principal activities are to discover, develop, manufacture and commercialise therapeutics for human health care including eye diseases, cancer and dermatological conditions. The products include visudyne, eligard, punctal plug and lemuteporfin. The eligard line of products are used for treatment of prostate cancer. Visudyne has been approved in over 75 countries and eligard is approved in over 60 countries. The Group's products are sold in the United States, Europe, Canada and other countries. On 18-Oct-2007 the Group acquired ForSight Newco II Inc, now known as QLT Plug Delivery Inc.
|
Not the Report you are looking for? Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
